Dr. Kaley Wilson is currently a Principal and the Director of Business Development at Quark Venture, a Vancouver based venture capital group that invests globally in health science. In her role Dr. Wilson actively supports company growth, strategic partnerships, technology advancement and exit through Director and Observer positions on Boards as well as leads portfolio companies as interim CEO (ARTMS, Sitka BioPharma) through to key milestone or further investment. Dr. Wilson is also Chair of GlycoNet's Commercialization Committee and a Director on their Board, a Director on the Board of Microbion, SeraGene, NZ Technologies and Crohn's and Colitis Canada. Dr. Wilson was previously a Director on the Board of Canary Medical, IOME and ARTMS. Prior to joining Quark Venture in October 2016, Dr. Wilson was Associate Director, Partnerships, at the Centre for Drug Research and Development. Dr. Wilson obtained her PhD in Dr. Pieter Cullis' laboratory at the University of British Columbia (UBC), Canada, in 2007 where she worked in close collaboration with senior scientists at INEX Pharmaceuticals on the immunomodulatory activity and vaccine potential of lipid encapsulated nucleic acids.